title: The role of adjuvant chemotherapy in early-stage and locally advanced non-small cell lung cancer.
abstract: Adjuvant chemotherapy benefits only a small proportion of patients in the setting of resected early-stage non-small cell lung cancer, and in unselected patients, any benefit is modest. Analysis of clinical trials of adjuvant chemotherapy revealed that differential expression of DNA repair proteins and a 15-gene expression profile affected outcomes with treatment. Biomarkers and gene expression profiles are now being studied in prospective clinical trials to gauge their value in selection of adjuvant therapy and individualization of therapy.
authors.affiliation: Department of Solid Tumor Oncology, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. shapirm@ccf.org
authors.forename: Marc
authors.initials: M
authors.lastname: Shapiro
mesh_terms: D054316:Biomarkers, Pharmacological / Q000032:analysis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D020869:Gene Expression Profiling; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000601:surgery; D011237:Predictive Value of Tests; D016896:Treatment Outcome
chemical_list: D054316:Biomarkers, Pharmacological